ArticleMMWR. Morbidity and mortality weekly report2019
Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000-2018.
Article in MMWR. Morbidity and mortality weekly report, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sero-prevalence of rubella among pregnant women in Sub-Saharan Africa: a meta-analysis.Human vaccines & immunotherapeutics · 2020Pooled it
- Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055.MMWR. Morbidity and mortality weekly report · 2025Article
- Rubella Vaccine Uptake among Women of Childbearing Age in Healthcare Settings.Healthcare (Basel, Switzerland) · 2023Article
- Article
- Epidemiological features and risk factors for measles and rubella in Taiwan during 2011 to 2020.Medicine · 2022Article
- Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study.The Lancet. Global health · 2022Article
- Article
- COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?Paediatric and perinatal epidemiology · 2022Review
- Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020.MMWR. Morbidity and mortality weekly report · 2022Article
- Article
- Susceptibility to Rubella Infection and Incidence of Congenital Rubella Infection: 6 Years Retrospective Study.International journal of general medicine · 2022Article
- Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.Advanced therapeutics · 2021Article
- Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.The Journal of infectious diseases · 2021Article
- Development of a Measles and Rubella Multiplex Bead Serological Assay for Assessing Population Immunity.Journal of clinical microbiology · 2021Article
- The period from prodromal fever onset to rash onset in laboratory-confirmed rubella cases: a cross-sectional study.BMC infectious diseases · 2021Article
- The Lancet Global Health Commission on Global Eye Health: vision beyond 2020.The Lancet. Global health · 2021Review
- Article
- Rubella Immunity among Italian Female Healthcare Workers: A Serological Study.International journal of environmental research and public health · 2020Article
- Article
- A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.Current opinion in virology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rubella is a leading cause of vaccine-preventable birth defects. Although rubella virus infection usually causes a mild febrile rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or a constellation of birth defects known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine (RCV) can provide lifelong protection (1). In 2011, the World Health Organization (WHO) updated guidance on the use of RCV and recommended capitalizing on the accelerated measles elimination activities as an opportunity to introduce RCV (1). The Global Vaccine Action Plan 2011-2020 (GVAP) includes a target to achieve elimination of rubella in at least five of the six WHO regions by 2020 (2). This report on the progress toward rubella and CRS control and elimination updates the 2017 report (3), summarizing global progress toward the control and elimination of rubella and CRS from 2000 (the initiation of accelerated measles control activities) and 2012 (the initiation of accelerated rubella control activities) to 2018 (the most recent data) using WHO immunization and surveillance data. Among WHO Member States,* the number with RCV in their immunization schedules has increased from 99 (52% of 191) in 2000 to 168 (87% of 194) in 2018
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.